Daratumumab eliminates CD38+ MM cells by inducing Fc receptor‐mediated apoptosis, antibody‐dependent cellular cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC).28 The gene discussed is CD38; the disease is Miyoshi myopathy.